title: Distribution of HLA-A, -B and -DRB1 alleles in patients with sudden sensorineural hearing loss.
abstract: This study was performed to investigate the association between human leukocyte antigen (HLA) and susceptibility to sudden sensorineural hearing loss in the Korean population. HLA-A and HLA-B typing using a standard microlymphocytotoxicity technique and HLA-DRB1 genotyping were performed in 35 patients with sudden sensorineural hearing loss and in 206 healthy controls. Prednisone (usual dose 60 mg/day) was administered for 6 days and tapered for an additional 4-6 days. Both initial hearing levels at the onset of deafness and final hearing levels after treatment were examined and evaluated for association with HLA alleles. The frequency of HLA-DRB1*14 was increased in patients with sudden sensorineural hearing loss compared with controls (relative risk [RR] = 2.7, p = 0.016). The frequencies of HLA-A2, -A31, -B52, -B61, -DRB1*04, -DRB1*11 and -DRB1*12 were slightly higher than in the controls, but did not reach statistical significance. When an association between the treatment results and HLA alleles was also evaluated, the frequency of HLA-DRB1*04 was found to be increased in the patients who did not respond to steroid treatment compared with both patients who responded well to steroid (50%, vs 16%, p = 0.034) and controls (RR = 3.0, p = 0.046). These results suggest that there is an association between HLA-DRB1*14 and disease susceptibility and that the presence of HLA-DRB1*04 may be an useful marker for predicting a poor prognosis in Korean patients with sudden sensorineural hearing loss.
authors: Department of Otolaryngology, Kangnam St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, South Korea. swyeo@cmc.cuk.ac.kr
authors: S W
authors: SW
authors: Yeo
authors: K H
authors: KH
authors: Chang
authors: B D
authors: BD
authors: Suh
authors: T G
authors: TG
authors: Kim
authors: H
authors: H
authors: Han
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone / Q000379:methods; D005260:Female; D005787:Gene Frequency / Q000235:genetics* / Q000276:immunology*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015234:HLA-A Antigens / Q000235:genetics* / Q000276:immunology*; D015235:HLA-B Antigens / Q000235:genetics* / Q000276:immunology*; D006684:HLA-DR Antigens / Q000235:genetics* / Q000276:immunology*; D059811:HLA-DRB1 Chains; D003639:Hearing Loss, Sudden / Q000175:diagnosis / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics / Q000276:immunology; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D020127:Recovery of Function; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D011241:Prednisone